Effect of Albendazole Dose on Clearance of Filarial Worms
Lymphatic Filariasis, Wuchereria Bancrofti Infection
About this trial
This is an interventional treatment trial for Lymphatic Filariasis focused on measuring Lymphatic Filariasis, Diethylcarbamazine, Microfilariae, Helminths, Nematode
Eligibility Criteria
- INCLUSION CRITERIA (SCREENING):
Age 18 years to 55 years inclusive.
Both genders.
Not pregnant or breastfeeding by history.
If selected, subject must be willing to spend 3 days on the Clinical Trials Unit of the Government General Hospital, Chennai India.
If selected, subject must be willing to undergo nighttime blood draws every 6 months for 2 years.
If selected, agree to have blood stored for future studies.
Ability to understand and sign the informed consent.
EXCLUSION CRITERIA (SCREENING):
Non-volunteers.
Age less than 18 years or greater than 55 years.
Pregnant or breastfeeding by history.
INCLUSION (TREATMENT):
Age 18 years to 55 years.
Men and non-pregnant or non-breastfeeding women.
Microfilarial levels greater than 50 mf/ml.
Willingness to spend 3 days on the Clinical Trials Unit of the Government General Hospital, Chennai India.
Willingness to undergo nighttime blood draws every 6 months for 2 years.
Ability to understand and sign the informed consent.
Hb levels for inclusion greater than 9 g/dL.
Normal Cr, ALT.
Willingness to have blood stored for future studies.
EXCLUSION (TREATMENT):
Non-volunteers.
Age less than 18 years or greater than 55 years.
Pregnancy or breast-feeding.
Hgb less than or equal to 9 g/dL.
Cr greater than 1.2/100 ml.
ALT greater than 30 U.
Alcohol consumption of more than 2 beers or other alcohol-containing drink/day within a week of each drug administration.
Temperature greater than 37.5 degrees C.
Serious medical illness.
History of benzimidazole allergy.
History of DEC allergy.
Use of albendazole or DEC within past 6 months.
Unwillingness to comply with required study visits.
Sites / Locations
- Tuberculosis Research Centre